<?xml version="1.0"?>
<presentation title="Atsushi IRISAWA" width="720.0000000" height="540.0000000" thmbWidth="78.0000000" thmbHeight="59.0000000" frameRate="24.0000000" looping="0" startingSlideShow="" pptVersion="2010" type="compound" hasExternalAudio="0" uid="{960D82CC-96CE-4808-B775-17F97F35928F}">
	<presenters>
		<presenter name="Atsushi IRISAWA, MD., PhD." title="The author have no financial conflicts of interest to disclose concerning the presentation." email="" web="" phone="" photoAssetId="">
			<bio>Asian EUS congress 2015
COI	Disclosure</bio>
		</presenter>
	</presenters>
	<references/>
	<soundAssets/>
	<sharedAssetsLibrary src="assets.swf"/>
	<graphicAssets>
		<graphicAsset id="imgAsset0" src="thmb1.swf" embedded="0"/>
		<graphicAsset id="imgAsset1" src="thmb2.swf" embedded="0"/>
		<graphicAsset id="imgAsset2" src="thmb3.swf" embedded="0"/>
		<graphicAsset id="imgAsset3" src="thmb4.swf" embedded="0"/>
		<graphicAsset id="imgAsset4" src="thmb5.swf" embedded="0"/>
		<graphicAsset id="imgAsset5" src="thmb6.swf" embedded="0"/>
		<graphicAsset id="imgAsset6" src="thmb7.swf" embedded="0"/>
		<graphicAsset id="imgAsset7" src="thmb8.swf" embedded="0"/>
		<graphicAsset id="imgAsset8" src="thmb9.swf" embedded="0"/>
		<graphicAsset id="imgAsset9" src="thmb10.swf" embedded="0"/>
		<graphicAsset id="imgAsset10" src="thmb11.swf" embedded="0"/>
		<graphicAsset id="imgAsset11" src="thmb12.swf" embedded="0"/>
		<graphicAsset id="imgAsset12" src="thmb13.swf" embedded="0"/>
		<graphicAsset id="imgAsset13" src="thmb14.swf" embedded="0"/>
		<graphicAsset id="imgAsset14" src="thmb15.swf" embedded="0"/>
		<graphicAsset id="imgAsset15" src="thmb16.swf" embedded="0"/>
		<graphicAsset id="imgAsset16" src="thmb17.swf" embedded="0"/>
		<graphicAsset id="imgAsset17" src="thmb18.swf" embedded="0"/>
	</graphicAssets>
	<backgroundSound soundAssetId="" looping="0" volume="1.0000000"/>
	<narration>
		<videoTracks>
			<videoTrack volume="1.0000000" src="ispring.resources_1d76f930.spr0_24560235" width="240" height="180">
				<startTimestamp slideIndex="0" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="0" stepIndex="0" timeOffset="13.6060000"/>
			</videoTrack>
			<videoTrack volume="1.0000000" src="ispring.resources_1d76f930.spr0_24560781" width="240" height="180">
				<startTimestamp slideIndex="1" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="1" stepIndex="0" timeOffset="7.1050000"/>
			</videoTrack>
			<videoTrack volume="1.0000000" src="ispring.resources_1d76f930.spr0_24562326" width="240" height="180">
				<startTimestamp slideIndex="2" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="2" stepIndex="0" timeOffset="36.0370000"/>
			</videoTrack>
			<videoTrack volume="1.0000000" src="ispring.resources_1d76f930.spr0_24563433" width="240" height="180">
				<startTimestamp slideIndex="3" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="3" stepIndex="0" timeOffset="22.2900000"/>
			</videoTrack>
			<videoTrack volume="1.0000000" src="ispring.resources_1d76f930.spr0_24564260" width="240" height="180">
				<startTimestamp slideIndex="4" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="4" stepIndex="0" timeOffset="16.0790000"/>
			</videoTrack>
			<videoTrack volume="1.0000000" src="ispring.resources_1d76f930.spr0_24566382" width="240" height="180">
				<startTimestamp slideIndex="5" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="5" stepIndex="0" timeOffset="51.3600000"/>
			</videoTrack>
			<videoTrack volume="1.0000000" src="ispring.resources_1d76f930.spr0_24568113" width="240" height="180">
				<startTimestamp slideIndex="6" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="6" stepIndex="0" timeOffset="38.6800000"/>
			</videoTrack>
			<videoTrack volume="1.0000000" src="ispring.resources_1d76f930.spr0_24570141" width="240" height="180">
				<startTimestamp slideIndex="7" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="7" stepIndex="0" timeOffset="48.4799995"/>
			</videoTrack>
			<videoTrack volume="1.0000000" src="ispring.resources_1d76f930.spr0_24571483" width="240" height="180">
				<startTimestamp slideIndex="8" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="8" stepIndex="0" timeOffset="29.6700000"/>
			</videoTrack>
			<videoTrack volume="1.0000000" src="ispring.resources_1d76f930.spr0_24573620" width="240" height="180">
				<startTimestamp slideIndex="9" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="9" stepIndex="0" timeOffset="51.9660000"/>
			</videoTrack>
			<videoTrack volume="1.0000000" src="ispring.resources_223aa900.spr0_24576257" width="240" height="180">
				<startTimestamp slideIndex="10" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="10" stepIndex="0" timeOffset="67.8899994"/>
			</videoTrack>
			<videoTrack volume="1.0000000" src="ispring.resources_223aa900.spr0_24580781" width="240" height="180">
				<startTimestamp slideIndex="11" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="11" stepIndex="0" timeOffset="114.9380000"/>
			</videoTrack>
			<videoTrack volume="1.0000000" src="ispring.resources_223aa900.spr0_24582013" width="240" height="180">
				<startTimestamp slideIndex="12" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="12" stepIndex="0" timeOffset="27.9099998"/>
			</videoTrack>
			<videoTrack volume="1.0000000" src="ispring.resources_223aa900.spr0_24583542" width="240" height="180">
				<startTimestamp slideIndex="13" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="13" stepIndex="0" timeOffset="37.8899994"/>
			</videoTrack>
			<videoTrack volume="1.0000000" src="ispring.resources_1d76f930.spr0_24585164" width="240" height="180">
				<startTimestamp slideIndex="14" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="14" stepIndex="0" timeOffset="39.4270000"/>
			</videoTrack>
			<videoTrack volume="1.0000000" src="ispring.resources_1d76f930.spr0_24586303" width="240" height="180">
				<startTimestamp slideIndex="15" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="15" stepIndex="0" timeOffset="26.6100000"/>
			</videoTrack>
			<videoTrack volume="1.0000000" src="ispring.resources_1d76f930.spr0_24587816" width="240" height="180">
				<startTimestamp slideIndex="16" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="16" stepIndex="0" timeOffset="32.9700000"/>
			</videoTrack>
			<videoTrack volume="1.0000000" src="ispring.resources_1d76f930.spr0_24589064" width="240" height="180">
				<startTimestamp slideIndex="17" stepIndex="0" timeOffset="0.0000000"/>
				<endTimestamp slideIndex="17" stepIndex="0" timeOffset="27.0390000"/>
			</videoTrack>
		</videoTracks>
	</narration>
	<settings>
		<navigation>
			<keyboard enabled="1">
				<actions>
					<action name="playPause">
						<shortcut code="32" control="0" shift="0"/>
					</action>
					<action name="nextSlide">
						<shortcut code="34" control="0" shift="0"/>
					</action>
					<action name="previousSlide">
						<shortcut code="33" control="0" shift="0"/>
					</action>
					<action name="nextStep">
						<shortcut code="13" control="0" shift="0"/>
					</action>
					<action name="previousStep">
						<shortcut code="13" control="0" shift="1"/>
					</action>
					<action name="firstSlide">
						<shortcut code="36" control="1" shift="0"/>
					</action>
					<action name="lastSlide">
						<shortcut code="35" control="1" shift="0"/>
					</action>
					<action name="lastViewedSlide">
						<shortcut code="8" control="0" shift="0"/>
					</action>
					<action name="slideStart">
						<shortcut code="36" control="0" shift="0"/>
					</action>
					<action name="slideEnd">
						<shortcut code="35" control="0" shift="0"/>
					</action>
					<action name="seekForward">
						<shortcut code="39" control="0" shift="0"/>
					</action>
					<action name="seekBackward">
						<shortcut code="37" control="0" shift="0"/>
					</action>
					<action name="volumeUp">
						<shortcut code="38" control="0" shift="0"/>
					</action>
					<action name="volumeDown">
						<shortcut code="40" control="0" shift="0"/>
					</action>
					<action name="toggleFullscreen">
						<shortcut code="70" control="1" shift="0"/>
					</action>
				</actions>
			</keyboard>
			<mouse enabled="1" target="step"/>
			<gesture zoom="1"/>
		</navigation>
		<skin>
			<colorSettings>
				<color id="button.content.normal">#FFFFFF</color>
				<color id="button.content.over">#FFFFFF</color>
				<color id="button.face.normal">#777777</color>
				<color id="button.face.over">#575757</color>
				<color id="companyLogo.background">#FFFFFF</color>
				<color id="hyperlink">#097CE7</color>
				<color id="listItem.face.over">#E8E8E8</color>
				<color id="listItem.face.pressed">#6E6E6E</color>
				<color id="listItem.label.over">#000000</color>
				<color id="listItem.label.pressed">#FFFFFF</color>
				<color id="listItem.label.visited">#A1A1A1</color>
				<color id="page.background">#8A8A8A</color>
				<color id="panel.background">#F7F7F7</color>
				<color id="panel.text">#323232</color>
				<color id="player.background">#D4D4D4</color>
				<color id="popup.background">#FFFFFF</color>
				<color id="progress.background">#6E6E6E</color>
				<color id="progress.loading">#D0D0D0</color>
				<color id="progress.playback">#A1A1A1</color>
				<color id="text">#4D4D4D</color>
			</colorSettings>
			<controlPanelSettings>
				<visible>true</visible>
				<showOutline>false</showOutline>
				<showPlayPause>true</showPlayPause>
				<showRewind>true</showRewind>
				<showVolumeControl>true</showVolumeControl>
				<showCCButton>false</showCCButton>
				<showPrevButton>true</showPrevButton>
				<showNextButton>true</showNextButton>
				<showSlideOnlyButton>true</showSlideOnlyButton>
				<progressBar>
					<visible>true</visible>
					<enabled>true</enabled>
					<showLabels>true</showLabels>
					<mode>slideTimeline</mode>
				</progressBar>
				<navigationMode>bySlides</navigationMode>
			</controlPanelSettings>
			<titlePanelSettings>
				<showLogo>false</showLogo>
				<visible>true</visible>
				<buttons>
					<button type="attachments" visible="true"/>
					<button type="presenterInfo" visible="true"/>
					<button type="markerTools" visible="true"/>
					<button type="notes" visible="false"/>
					<button type="outline" visible="false"/>
				</buttons>
			</titlePanelSettings>
			<outlinePanelSettings>
				<numberEntries>true</numberEntries>
				<highlightViewedEntries>true</highlightViewedEntries>
				<thumbnails>true</thumbnails>
				<search>true</search>
				<multilevel>true</multilevel>
			</outlinePanelSettings>
			<sidePanelSettings>
				<showAtLeft>true</showAtLeft>
				<showLogo>false</showLogo>
				<showPresenterInfo>false</showPresenterInfo>
				<showPresenterVideo>true</showPresenterVideo>
				<visible>true</visible>
				<tabsPanel>
					<showOutline>true</showOutline>
					<showNotes>true</showNotes>
				</tabsPanel>
			</sidePanelSettings>
		</skin>
		<appearance fullScreen="1" showSlidePreloader="1"/>
		<playback autoStart="1" syncWithVideoNarration="1" enableVideoControl="1" resumePresentationPlayback="never"/>
	</settings>
	<slides embedded="0">
		<slide index="0" title="Asian EUS congress 2015 COI Disclosure" titleNormalized="asian eus congress 2015 coi disclosure" src="slide1.swf" size="16567" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset0" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="13.6089997"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>Asian EUS congress 2015
COI	Disclosure
Atsushi IRISAWA, MD., PhD.
The author have no financial conflicts of interest to disclose concerning the presentation.</text>
		</slide>
		<slide index="1" title="EUS-guided immunotherapy for pancreatic cancer" titleNormalized="eus-guided immunotherapy for pancreatic cancer" src="slide2.swf" size="440725" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset1" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="7.1090001"/>
			</animationSteps>
			<notes/>
			<notesNormalized/>
			<notesHtml/>
			<text>EUS-guided immunotherapy
for pancreatic cancer 
Atsushi Irisawa, MD, PhD. 
Fukushima Medical University Aizu Medical Center Aizuwakamatsu, JAPAN.</text>
		</slide>
		<slide index="2" title="EUS-FNI (injection/implantation) for pancreatic cancer in the past literatures" titleNormalized="eus-fni (injection/implantation) for pancreatic cancer in the past literatures" src="slide3.swf" size="19599" advanceOnTime="1" framesCount="277" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset2" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="276" playTime="11.5000000" pauseTime="24.5400009"/>
			</animationSteps>
			<notes>This table shows EUS-guided fine needle injection and implantation for pancreatic cancer in the past literatures. 

You can see the various therapeutic agents for the treatment.
From the difference of therapeutic agents, EUS-guided fine needle injection and implantation is divided into 3 categories, physiochemical therapy, molecular biological therapy, and immunological therapy.
 </notes>
			<notesNormalized>this table shows eus-guided fine needle injection and implantation for pancreatic cancer in the past literatures. 

you can see the various therapeutic agents for the treatment.
from the difference of therapeutic agents, eus-guided fine needle injection and implantation is divided into 3 categories, physiochemical therapy, molecular biological therapy, and immunological therapy.
</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;This table shows EUS-guided fine needle injection and implantation for pancreatic cancer in the past literatures. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;You can see the various therapeutic agents for the treatment.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;From the difference of therapeutic agents, EUS-guided fine needle injection and implantation is divided into 3 categories, physiochemical therapy, molecular biological therapy, and immunological therapy.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt; &lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>EUS-FNI (injection/implantation) for pancreatic cancer in the past literatures
Fundamentals
Objects
Physicochemical therapy
Immunological therapy
Molecular biological therapy
Agents
Brachytherapy
Ablation
Chemotherapy
Cystic mass, pNET
Ethanol
Cancer 
Radiation seeds
Cancer 
Gelled Paclitaxel
Cytoimplant 
Lymphocytes
Dendritic cells
Cancer 
Cancer, Metastasis
Gene therapy
TNF-erade 
ONYX-015
Cancer 
Cancer 
Irinotecan beads</text>
		</slide>
		<slide index="3" title="EUS-FNI for pancreatic cancer in the past literatures" titleNormalized="eus-fni for pancreatic cancer in the past literatures" src="slide4.swf" size="8054" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset3" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="22.2890009"/>
			</animationSteps>
			<notes>Until now, for EUS-guided immunotherapy, 2 kinds of cells, lymphocytes and dendritic cells were directly implanted into the pancreatic tumor. </notes>
			<notesNormalized>until now, for eus-guided immunotherapy, 2 kinds of cells, lymphocytes and dendritic cells were directly implanted into the pancreatic tumor.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;Until now, for EUS-guided immunotherapy, 2 kinds of cells, lymphocytes and dendritic cells were directly implanted into the pancreatic tumor. &lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>EUS-FNI for pancreatic cancer in the past literatures
Fundamentals
Objects
Physicochemical therapy
Immunological therapy
Molecular biological therapy
Agents
Brachytherapy
Ablation
Chemotherapy
Cystic mass, pNET
Ethanol
Cancer 
Radiation seeds
Cancer 
Gelled Paclitaxel
Cytoimplant 
Lymphocytes
Dendritic cells
Cancer 
Cancer, Metastasis
Gene therapy
TNF-erade 
ONYX-015
Cancer 
Cancer 
Irinotecan beads</text>
		</slide>
		<slide index="4" title="What is the significance of EUS-guided immunotherapy in comparison with other EUS-guided treatment?" titleNormalized="what is the significance of eus-guided immunotherapy in comparison with other eus-guided treatment?" src="slide5.swf" size="1220" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset4" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="16.0789999"/>
			</animationSteps>
			<notes>In the next, I will talk about the significance of EUS-guided immunotherapy in comparison with other EUS-guided treatment for the pancreatic cancer。</notes>
			<notesNormalized>in the next, i will talk about the significance of eus-guided immunotherapy in comparison with other eus-guided treatment for the pancreatic cancer。</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;In the next, I will talk about the significance of EUS-guided immunotherapy in comparison with other EUS-guided treatment for the pancreatic cancer。&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>What is the significance of 
EUS-guided immunotherapy
in comparison with other EUS-guided treatment?</text>
		</slide>
		<slide index="5" title="Feasibility of EUS-FNI of irinotecan-loaded microspheres into the swine pancreas." titleNormalized="feasibility of eus-fni of irinotecan-loaded microspheres into the swine pancreas." src="slide6.swf" size="77759" advanceOnTime="1" framesCount="25" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset5" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="24" playTime="1.0000000" pauseTime="50.3600006"/>
			</animationSteps>
			<notes>This paper showed the possibilities of EUS-guided chemotherapy. You can see the injected beads.

EUS-based chemotherapy techniques showed minimal invasive treatment option for unresectable pancreatic cancer.
But the limitation is treatment for local advanced pancreatic cancer.
</notes>
			<notesNormalized>this paper showed the possibilities of eus-guided chemotherapy. you can see the injected beads.

eus-based chemotherapy techniques showed minimal invasive treatment option for unresectable pancreatic cancer.
but the limitation is treatment for local advanced pancreatic cancer.
</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;This paper showed the possibilities of EUS-guided chemotherapy. You can see the injected beads.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;&lt;b&gt;EUS-based chemotherapy techniques showed minimal invasive treatment option for unresectable pancreatic cancer.&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="11"&gt;But the limitation is treatment for local advanced pancreatic cancer.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Feasibility of EUS-FNI of irinotecan-loaded microspheres into the swine pancreas.
Beads (the time-released delivery of 
 the chemotherapeutic agent irinotecan) 
 were injected into pancreas.

This technique as feasible and safe. 

Karaca C, et al. GIE. 73, 2011.
Chemotherapy
EUS-based chemotherapy will be minimal invasive
 treatment option for unresectable pancreatic cancer.
Limitation: for local advanced cancer</text>
		</slide>
		<slide index="6" title="Significance of Immunotherapy" titleNormalized="significance of immunotherapy" src="slide7.swf" size="1829" advanceOnTime="1" framesCount="589" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset6" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="588" playTime="24.5000000" pauseTime="14.1800003"/>
			</animationSteps>
			<notes>So, I summarize the significance of immunotherapy for pancreatic cancer.
</notes>
			<notesNormalized>so, i summarize the significance of immunotherapy for pancreatic cancer.
</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;So, I summarize the significance of immunotherapy for pancreatic cancer.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Pancreatic cancer is regarded as a systemic disease even if imaging modalities reveal no metastasis. 
Therefore, immunotherapy targeting not only main tumor but also metastasis/dissemination is expected as new treatment for pancreatic cancer. 
Direct injection of anti-cancer drugs into the tumor may be effective for local advanced cancer. 
Significance of Immunotherapy</text>
		</slide>
		<slide index="7" title="Allogeneic mixed lymphocyte culture delivered by EUS-FNI for advanced pancreatic carcinoma" titleNormalized="allogeneic mixed lymphocyte culture delivered by eus-fni for advanced pancreatic carcinoma" src="slide8.swf" size="2901" advanceOnTime="1" framesCount="1009" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset7" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="1008" playTime="42.0000000" pauseTime="6.4799995"/>
			</animationSteps>
			<notes>This s the first report about EUS-guided immunotherapy for pancreatic cancer.
Professor Chang performed EUS-guided cyto-implantation into unresectable local pancreatic cancer.

It is difficult to evaluate the results, but, this paper indicated the EUS-guided immunotherapy is feasible and safe.  </notes>
			<notesNormalized>this s the first report about eus-guided immunotherapy for pancreatic cancer.
professor chang performed eus-guided cyto-implantation into unresectable local pancreatic cancer.

it is difficult to evaluate the results, but, this paper indicated the eus-guided immunotherapy is feasible and safe.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;This s the first report about EUS-guided immunotherapy for pancreatic cancer.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;Professor Chang performed EUS-guided cyto-implantation into unresectable local pancreatic cancer.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;It is difficult to evaluate the results, but, this paper indicated the EUS-guided immunotherapy is feasible and safe.  &lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Allogeneic mixed lymphocyte culture delivered by EUS-FNI for advanced pancreatic carcinoma 
Eight patients with unresectable adenocarcinoma of the pancreas were enrolled. 

There were 2 partial responses and 1 minor response, with a median survival of 13.2 months. 

There were no procedure-related complications. 
Chang KJ, et al. Cancer 88, 2000. 
EUS-guided immunotherapy is feasible.</text>
		</slide>
		<slide index="8" title="EUS-guided FNI of immature dendritic cells into advanced pancreatic cancer" titleNormalized="eus-guided fni of immature dendritic cells into advanced pancreatic cancer" src="slide9.swf" size="6455" advanceOnTime="1" framesCount="13" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset8" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="12" playTime="0.5000000" pauseTime="29.1700001"/>
			</animationSteps>
			<notes>7 years after Chang’s report, we showed the pilot study the EUS-guided immnotherapy using dendritic cells for unresectable advanced pancreatic cancer refractory to GEM.
So, I introduce our study.</notes>
			<notesNormalized>7 years after chang’s report, we showed the pilot study the eus-guided immnotherapy using dendritic cells for unresectable advanced pancreatic cancer refractory to gem.
so, i introduce our study.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;7 years after Chang’s report, we showed the pilot study the EUS-guided immnotherapy using dendritic cells &lt;b&gt;for unresectable advanced pancreatic cancer refractory to GEM.&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;&lt;b&gt;So, I introduce our study.&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Irisawa A et al. Pancreas 35, 2007. 
EUS-guided FNI of immature dendritic cells into advanced pancreatic cancer.
Intratumorally injected own immature dendritic cells would initiate a significant tumor specific immune response.</text>
		</slide>
		<slide index="9" title="Dendritic cell (DC) is potent antigen-presenting cell for induction of primary T cell-dependent immune responses" titleNormalized="dendritic cell (dc) is potent antigen-presenting cell for induction of primary t cell-dependent immune responses" src="slide10.swf" size="128923" advanceOnTime="1" framesCount="997" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset9" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="996" playTime="41.5000000" pauseTime="10.4700012"/>
			</animationSteps>
			<notes>This theory is “Intratumorally injected immature dendritic cells would initiate a significant tumor specific immune response.”
Dendritic cells (DCs), are potent antigen-presenting cells for induction of primary T-cell-dependent immune responses.

So, Direct injection of DCs into the tumor will conduce the  antitumor immune response.


</notes>
			<notesNormalized>this theory is “intratumorally injected immature dendritic cells would initiate a significant tumor specific immune response.”
dendritic cells (dcs), are potent antigen-presenting cells for induction of primary t-cell-dependent immune responses.

so, direct injection of dcs into the tumor will conduce the antitumor immune response.


</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;This theory is “Intratumorally injected immature dendritic cells would initiate a significant tumor specific immune response.”&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;&lt;b&gt;Dendritic cells (DCs), are potent antigen-presenting cells for induction of primary T-cell-dependent immune responses.&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;&lt;b&gt;So, Direct injection of DCs into the tumor will conduce the  antitumor immune response.&lt;/font&gt;&lt;font size="18"&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;</notesHtml>
			<text>Dendritic cell (DC) is potent antigen-presenting cell for induction of primary T cell-dependent immune responses.
Injection of DCs
CD4
CD8
No injection
⇒ Direct injection of DCs into the tumor will
 conduce the antitumor immune response.</text>
		</slide>
		<slide index="10" title="We performed this treatment for 7 patients refractory to Gemcitabine as a pilot study" titleNormalized="we performed this treatment for 7 patients refractory to gemcitabine as a pilot study" src="slide11.swf" size="37786" advanceOnTime="1" framesCount="1549" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset10" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="1548" playTime="64.5000000" pauseTime="3.3899994"/>
			</animationSteps>
			<notes>Mechanisms of this therapy.
When immature DCs are injected into the tumor,
DCs acquire all tumor antigens. 
and
DCs maturate,
and induce cytotoxic T-cells,
and DCs present tumor antigen to the CTL.
Consequently, 
CTL having anti tumor activity will attack the tumor cells.

Intratumorally injected immature DCs would acquire and process tumor antigens in situ, migrate to regional lymphoid organs, and initiate a significant tumor specific immune response. </notes>
			<notesNormalized>mechanisms of this therapy.
when immature dcs are injected into the tumor,
dcs acquire all tumor antigens. 
and
dcs maturate,
and induce cytotoxic t-cells,
and dcs present tumor antigen to the ctl.
consequently, 
ctl having anti tumor activity will attack the tumor cells.

intratumorally injected immature dcs would acquire and process tumor antigens in situ, migrate to regional lymphoid organs, and initiate a significant tumor specific immune response.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;Mechanisms of this therapy.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;When immature DCs are injected into the tumor,&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;DCs acquire all tumor antigens. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;and&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;DCs maturate,&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;and induce cytotoxic T-cells,&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;and DCs present tumor antigen to the CTL.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;Consequently, &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;CTL having anti tumor activity will attack the tumor cells.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;Intratumorally injected immature DCs would acquire and process tumor antigens in situ, migrate to regional lymphoid organs, and initiate a significant tumor specific immune response. &lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Antitumor activity
Tumor cells
CTL
CTL
Tumor cells
CTL
CTL
Ag presentation to CTL
Mature DCs
Immature DC
Acquire
all tumor antigens
We performed this treatment for 7 patients refractory to Gemcitabine as a pilot study.</text>
		</slide>
		<slide index="11" title="Eus-guided FNI of dendritic cells into advanced pancreatic carcinoma(video)" titleNormalized="eus-guided fni of dendritic cells into advanced pancreatic carcinoma(video)" src="slide12.swf" size="386424" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset11" presenterIndex="0">
			<sounds/>
			<videos>
				<video id="video0" videoClipId="ispring.resources_1d76fa10.spr0_24548286" slides="1" repeat="1" volume="0.8000000" posterFrameId="ispring.resources_1d76fa10.spr2_24548286" playFullScreen="0" hideWhenNotPlaying="0" rewindAfterPlaying="0"/>
			</videos>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands>
				<pauseVideo frameIndex="0" videoId="video0"/>
			</videoCommands>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="114.9390024"/>
			</animationSteps>
			<notes>You can see a video. 
This is me. she is Japanese young lady, who is an assistant for retaining the scope. At first, needle is puncture into the tumor just like FNA.  
Now we perform injection of dendritic cells into the tumor. </notes>
			<notesNormalized>you can see a video. 
this is me. she is japanese young lady, who is an assistant for retaining the scope. at first, needle is puncture into the tumor just like fna. 
now we perform injection of dendritic cells into the tumor.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;You can see a video. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;This is me. she is Japanese young lady, who is an assistant for retaining the scope. At first, needle is puncture into the tumor just like FNA.  &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;Now we perform injection of dendritic cells into the tumor. &lt;/font&gt;&lt;/p&gt;</notesHtml>
		</slide>
		<slide index="12" title="Results" titleNormalized="results" src="slide13.swf" size="21365" advanceOnTime="1" framesCount="13" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset12" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="12" playTime="0.5000000" pauseTime="27.4099998"/>
			</animationSteps>
			<notes>This table shows the results of 7 patients.
Although all patients were stage 4, and  were refractory to repeated systemic administration of gemcitabine, 

mean survival period was 9.9 months without major complications.
It is considered this treatment was meaningful for treatment of advanced pancreatic cancer. </notes>
			<notesNormalized>this table shows the results of 7 patients.
although all patients were stage 4, and were refractory to repeated systemic administration of gemcitabine, 

mean survival period was 9.9 months without major complications.
it is considered this treatment was meaningful for treatment of advanced pancreatic cancer.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;This table shows the results of 7 patients.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;Although all patients were stage 4, and  were refractory to repeated systemic administration of gemcitabine, &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;mean survival period was 9.9 months without major complications.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;It is considered this treatment was meaningful for treatment of advanced pancreatic cancer. &lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Results
Case
Patients
Age, Gender
Prior therapy
 Stage
Status before DCs injection
Response to DCs injection
Response
Survival after diagnosis
Treatment
Times of inj.
1
2
3
4
5
54 m
Ⅳb
Rad., GEM
 4
MR, CA19-9↓
 6 m
54 m
GEM, UFT
21
MR, CA19-9↓
14m
52 m
GEM
 2
PD, CA19-9↑
 5 m
62 m
GEM, S1
 6
 7 m
56 m
 3
 6 m
Rad., GEM
6
42 f
11
SD, CA19-9↓
10m
GEM
Ⅳb
Ⅳb
Ⅳb
Ⅳb
Ⅳb
Metastasis
Liver,
peritoneum
liver
liver
liver
liver
7
62 f
18
21m
GEM
Ⅳa
none
PD, CA19-9↑
PD, CA19-9↑
SD, CA19-9 ↓
Liver,
peritoneum
Mean 9.9 months</text>
		</slide>
		<slide index="13" title="Case presentation (54 yo, male)" titleNormalized="case presentation (54 yo, male)" src="slide14.swf" size="473281" advanceOnTime="1" framesCount="1" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset13" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="0" playTime="0.0010000" pauseTime="37.8889994"/>
			</animationSteps>
			<notes>I show the impressive  case presentation. This middle age male patient was pancreatic cancer with multiple liver metastasis.
You can see the CT image, a pancreatic tumor in the pancreatic tail with multiple liver metastasis. 
At first, we performed the systemic chemotherapy using GEM. Unfortunately, it was no response. Therefore, 
We performed EUS-FNI, intratumoral injection of DCs. </notes>
			<notesNormalized>i show the impressive case presentation. this middle age male patient was pancreatic cancer with multiple liver metastasis.
you can see the ct image, a pancreatic tumor in the pancreatic tail with multiple liver metastasis. 
at first, we performed the systemic chemotherapy using gem. unfortunately, it was no response. therefore, 
we performed eus-fni, intratumoral injection of dcs.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;I show the impressive  case presentation. This middle age male patient was pancreatic cancer with multiple liver metastasis.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;You can see the CT image, a pancreatic tumor in the pancreatic tail with multiple liver metastasis. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;At first, we performed the systemic chemotherapy using GEM. Unfortunately, it was no response. Therefore, &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;We performed EUS-FNI, intratumoral injection of DCs. &lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Case presentation (54 yo, male)</text>
		</slide>
		<slide index="14" title="Clinical course on EUS of the primary tumor" titleNormalized="clinical course on eus of the primary tumor" src="slide15.swf" size="272168" advanceOnTime="1" framesCount="289" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset14" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="288" playTime="12.0000000" pauseTime="27.4300003"/>
			</animationSteps>
			<notes>You can see the clinical course on EUS.
.
the main tumor was exactly similar during DCs injection. 
And liver metastasis was also controlled until 10 months after initial treatment.
However, from 11 months after initial treatment, liver metastasis had increased against the treatment. 
The patient was dead of cancer in 14 months after starting DCs injection.

In my opinion, the tumor antigen might  change. </notes>
			<notesNormalized>you can see the clinical course on eus.
.
the main tumor was exactly similar during dcs injection. 
and liver metastasis was also controlled until 10 months after initial treatment.
however, from 11 months after initial treatment, liver metastasis had increased against the treatment. 
the patient was dead of cancer in 14 months after starting dcs injection.

in my opinion, the tumor antigen might change.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;You can see the clinical course on EUS.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;the main tumor was exactly similar during DCs injection. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;And liver metastasis was also controlled until 10 months after initial treatment.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;However, from 11 months after initial treatment, liver metastasis had increased against the treatment. &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;The patient was dead of cancer in 14 months after starting DCs injection.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;In my opinion, the tumor antigen might  change. &lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>1 week later
23mm
SV
5 weeks later
12mm
SV
SV
23mm
8 weeks later
SV
23mm
24 weeks later
Clinical course on EUS of the primary tumor 
24mm
Starting line
Splenic vein (SV)</text>
		</slide>
		<slide index="15" title="Our next step," titleNormalized="our next step," src="slide16.swf" size="9513" advanceOnTime="1" framesCount="313" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset15" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="312" playTime="13.0000000" pauseTime="13.6100006"/>
			</animationSteps>
			<notes>We tried in next stage, 

for resectable cancer before surgical operation.

In this study, one patient with with distant lymph node metastasis, stage 4, survived more than 5 years without requiring adjuvant therapy.
This methodology may open the next door.</notes>
			<notesNormalized>we tried in next stage, 

for resectable cancer before surgical operation.

in this study, one patient with with distant lymph node metastasis, stage 4, survived more than 5 years without requiring adjuvant therapy.
this methodology may open the next door.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;We tried in next stage, &lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;for resectable cancer before surgical operation.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;In this study, one patient with with distant lymph node metastasis, stage 4, survived more than 5 years without requiring adjuvant therapy.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;This methodology may open the next door.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>Our next step,
Phase I trial of preoperative intratumoral injection of immature DCs and OK-432 for resectable pancreatic cancer patients (n=5).
Endo H, Irisawa A, Goto M, et al. J Hepatobiliary Pancreat Sci. 19, 2012.
In this study, one patient with with distant lymph node metastasis, stage 4, survived more than 5 years without requiring adjuvant therapy.</text>
		</slide>
		<slide index="16" title="A combination therapy of GEM with immunotherapy for unresectable locally advanced pancreatic cancer" titleNormalized="a combination therapy of gem with immunotherapy for unresectable locally advanced pancreatic cancer" src="slide17.swf" size="2043" advanceOnTime="1" framesCount="373" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset16" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="372" playTime="15.5000000" pauseTime="17.4700012"/>
			</animationSteps>
			<notes>After our study, Professor Hirooka showed the combination therapy, gemcitabine and immunotherapy for pancreatic cancer.

They performed for 5 patients, and showed 3 of the 5 patients demonstrated effective responses to this clinical trial without serious complications.</notes>
			<notesNormalized>after our study, professor hirooka showed the combination therapy, gemcitabine and immunotherapy for pancreatic cancer.

they performed for 5 patients, and showed 3 of the 5 patients demonstrated effective responses to this clinical trial without serious complications.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;After our study, Professor Hirooka showed the combination therapy, gemcitabine and immunotherapy for pancreatic cancer.&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;They performed for 5 patients, and showed 3 of the 5 patients demonstrated effective responses to this clinical trial without serious complications.&lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>A combination therapy of GEM with immunotherapy for unresectable locally advanced pancreatic cancer.
Hirooka Y, et al. Pancreas 2009 ;38:e69-74. 
5 patients were enrolled.

Intravenous GEM administration at 1000 mg/m2 (day 1) and the EUS-FNI DCs into a tumor, followed by intravenous infusion of lymphokine-activated killer cells (day 4), at 2-week intervals.

3 of the 5 patients demonstrated effective responses to this clinical trial; 1 had partial remission and 2 had long stable disease more than 6 months. 

No serious treatment-related adverse events were observed.</text>
		</slide>
		<slide index="17" title="In conclusion, EUS-guided immunotherapy has opened new and exciting clinical applications for management of cancers." titleNormalized="in conclusion, eus-guided immunotherapy has opened new and exciting clinical applications for management of cancers." src="slide18.swf" size="34040" advanceOnTime="1" framesCount="337" hasEmbeddedFlashClip="0" hidden="0" level="0" advanceOnClick="1" thumbnailAssetId="imgAsset17" presenterIndex="0">
			<sounds/>
			<videos/>
			<transitionEffect name="" duration="0.0000000" soundId="" looped="0"/>
			<soundCommands/>
			<videoCommands/>
			<animationSteps>
				<step start="0" end="336" playTime="14.0000000" pauseTime="13.0400009"/>
			</animationSteps>
			<notes>So, ladies and gentleman, in conclusion of mu presentation,

For greater development in this field, I think it will be important to collaborate between endosonographers, engineer and basic scientist. </notes>
			<notesNormalized>so, ladies and gentleman, in conclusion of mu presentation,

for greater development in this field, i think it will be important to collaborate between endosonographers, engineer and basic scientist.</notesNormalized>
			<notesHtml>&lt;p&gt;&lt;font size="12"&gt;So, ladies and gentleman, in conclusion of mu presentation,&lt;/font&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;font size="12"&gt;For greater development in this field, I think it will be important to collaborate between endosonographers, engineer and basic scientist. &lt;/font&gt;&lt;/p&gt;</notesHtml>
			<text>In conclusion,
EUS-guided immunotherapy has opened new and exciting clinical applications for management of cancers. 
Basic scientist
Endosonographer
Engineer
Collaboration</text>
		</slide>
	</slides>
</presentation>
